SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation ...

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find ...

The gene therapy for neurological diseases market is poised for growth due to rising neurological disorder prevalence, demand ...

Partnership leverages AI-powered genome design to optimize AAV constructs, accelerate lead candidate selection, and improve drug substance manufacturability for rare and ultra-rare neuromuscular ...

US biotech Cirrus Therapeutics has emerged from stealth with $11 million in seed financing to advance a gene therapy for dry ...

Newly discovered diversity in the wheat genome could offer new opportunities to improve and ‘climate-proof’ one of the world’s most important staple crops.

The death of William (Bill) Rutter at the grand old age of 97 in July reminded me to remember not only him, but several of the other pioneers of our industry—lest we should forget them.

Founded in 2023 and headquartered in Cambridge, Massachusetts, Cirrus was spun out from University of Bristol research in ...

Class Biopharma Companies and Driving Late-Stage Development and Commercial ExecutionArthur Tzianabos Resumes Chairman of the ...

At first glance, plants may seem passive – but beneath their stillness lies a world of complexity and constant activity.

MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemia Oral presentation highlights safe, robust, and durable reduction of apoC-III ...

Mary Brunkow of the Seattle-based Institute for Systems Biology, Fred Ramsdell of Sonoma Biotherapeutics, and David Baker of the UW's Institute for Protein Design were honored for their research.